[1]刘建辉,杨 娅,况时祥,等.补脾强力复方治疗重症肌无力患者的疗效及其对 血清细胞因子的影响[J].医学信息,2019,32(16):73-75.[doi:10.3969/j.issn.1006-1959.2019.16.022]
　LIU Jian-hui,YANG Ya,KUANG Shi-xiang,et al.Effect of Invigorating Spleen and Strengthening Compound on Patients with Myasthenia Gravis and Its Effect on Serum Cytokines[J].Journal of Medical Information,2019,32(16):73-75.[doi:10.3969/j.issn.1006-1959.2019.16.022]
点击复制

补脾强力复方治疗重症肌无力患者的疗效及其对 血清细胞因子的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年16期
页码:
73-75
栏目:
论著
出版日期:
2019-08-15

文章信息/Info

Title:
Effect of Invigorating Spleen and Strengthening Compound on Patients with Myasthenia Gravis and Its Effect on Serum Cytokines
文章编号:
1006-1959（2019）16-0073-06
作者:
刘建辉1; 杨 娅2; 况时祥1; 杨 辉1; 唐桂华1; 宋先红1
1.贵州中医药大学第二附属医院神经内科，贵州 贵阳 550003； 2.贵州中医药大学，贵州 贵阳 550025
Author(s):
LIU Jian-hui1; YANG Ya2; KUANG Shi-xiang1; YANG Hui1; TANG Gui-hua1; SONG Xian-hong1
1.Department of Neurology,the Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang 550003,Guizhou,China; 2.Guizhou University of Traditional Chinese Medicine,Guiyang 550025,Guizhou,China
关键词:
补脾强力复方; 重症肌无力; 细胞因子
Keywords:
Key words：Spleen-strong combination; Myasthenia gravis; Cytokines
分类号:
R746.1
DOI:
10.3969/j.issn.1006-1959.2019.16.022
文献标志码:
A
摘要:
目的 探讨补脾强力复方治疗重症肌无力患者的临床疗效及血清细胞因子的影响。方法 选择2017年9月~2019年5月在我科门诊及住院治疗的重症肌无力Ⅰ型和Ⅱa型患者共60例，采用随机数字表法分为对照组28例和治疗组32例。对照组给予强的松联合溴吡斯的明治疗，治疗组在对照组基础上加用补脾强力复方治疗，疗程均为12周，采用重症肌无力临床相对评分法和临床绝对评分法评估患者临床疗效，用ELISA法检测两组患者外周血AchR-Ab、IFN-γ、TNF-α、IL-4、IL-17水平，观察补脾强力复方的临床疗效、细胞因子水平变化及不良反应发生情况。结果 治疗组愈显率为75.00%，与对照组的68.00%比较，差异无统计学意义（P＞0.05）；治疗组总有效率为91.00%，高于对照组的71.00%（P＜0.05）。治疗后两组AChR-Ab、IFN-γ、TNF-α、IL-4、IL-17水平均低于治疗前（P＜0.05），治疗组AChR Ab、IFN-γ、IL-17水平降低优于对照组（P＜0.05）；两组IL-4、TNF-α变化比较，差异无统计学意义（P＞0.05）。两组治疗期间均未见腹泻、腹痛、恶心、皮疹等不良反应，差异无统计学意义（P＞0.05）。结论 补脾强力复方可在一定程度上提高重症肌无力的近期临床疗效，其机制与下调血清IFN-γ和IL-17 水平、降低血清AChR-Ab水平可能有关。
Abstract:
Abstract：Objective To investigate the clinical efficacy and serum cytokine effect of spleen-strengthening compound in the treatment of patients with myasthenia gravis. Methods A total of 60 patients with myasthenia gravis type I and IIa who were treated in our outpatient department and hospitalized in our hospital from September 2017 to May 2019 were randomly divided into the control group (n=28) and the treatment group (n=32). The control group was treated with prednisone plus bromide, and the treatment group was treated with spleen-strengthening compound on the basis of the control group. The course of treatment was 12 weeks. The patients were evaluated by the clinical relative score of myasthenia gravis and the clinical absolute score. Clinical efficacy, ELISA method was used to detect the levels of AchR-Ab, IFN-γ, TNF-α, IL-4 and IL-17 in peripheral blood of the two groups. The clinical efficacy, cytokine level and adverse reactions of spleen-strengthening compound were observed.Results The cure rate of the treatment group was 75.00%, compared with 68.00% of the control group, the difference was not statistically significant (P>0.05); the total effective rate of the treatment group was 91.00%, which was higher than that of the control group 71.00%(P<0.05). After treatment, the levels of AChR-Ab, IFN-γ, TNF-α, IL-4 and IL-17 in the two groups were lower than those before treatment (P<0.05). The treatment group AChR Ab, IFN-γ, The level of IL-17 was lower than that of the control group(P<0.05). There was no significant difference in the changes of IL-4 and TNF-α between the two groups (P>0.05). No adverse reactions such as diarrhea, abdominal pain, nausea, and rash were observed during the two treatment periods,the difference was not statistically significant (P>0.05). Conclusion The combination of spleen and strong spleen can improve the short-term clinical efficacy of myasthenia gravis to a certain extent. The mechanism may be related to the down-regulation of serum IFN-γ and IL-17 levels and the decrease of serum AChR-Ab levels.

参考文献/References:

[1]Gilhus NE.Myasthenia Gravis[J].N Engl J Med,2016,375(26):2570-2581. [2]易芳芳,朱雯华,赵重波.重症肌无力与细胞因子[J].中国临床神经科学,2014,22(4):470-474. [3]Chen S,Xu M,Zhou X,et al.Chinese Herbal Medicine for Myasthenia Gravis:A Systematic Review and Meta-Analysis[J].Front Pharmacol,2018(9):969. [4]中华医学会神经病学分会神经免疫学组.中国重症肌无力诊断和治疗指南2015[J].中华神经科杂志,2015,48(11):934． [5]乞国艳,刘鹏,顾珊珊,等.健脾益气补肝健肾中药治疗重症肌无力眼肌型患儿的乙酰胆碱受体抗体的临床研究[J].中华中医药学刊,2017(3):624-628. [6]谢地,曹月红,刘凤斌.国医大师邓铁涛治疗脾胃疾病学术思想探讨[J].中医药学报,2014(3):5-7. [7]董风林,王健.重症肌无力中医药研究[J].长春中医药大学学报,2015,31(3):520-522. [8]况时祥.补脾益肾扶阳为主治疗重症肌无力临床体会[J].山东中医杂志,2008,8(27):526-527. [9]况时祥,况耀錾.重症肌无力从湿毒论治探讨[J].湖南中医杂志,2013,29(12):5-7. [10]刘建辉,况时祥,张献文,等.158例重症肌无力患者中医证候和临床特点相关性探讨[J].中国中医药现代远程教育,2017,15(22):63-65. [11]王静,周双秀,况时祥.补脾强力复方对重症肌无力胸腺切除术前后干预的临床研究[J].时珍国医国药,2016,27(2):383-385.

相似文献/References:

[1]马艳艳,刘建军.肌无力危象的治疗研究进展[J].医学信息,2019,32(06):45.[doi:10.3969/j.issn.1006-1959.2019.06.016]
　MA Yan-yan,LIU Jian-jun.Progress in the Treatment of Myasthenia Crisis[J].Journal of Medical Information,2019,32(16):45.[doi:10.3969/j.issn.1006-1959.2019.06.016]
[2]屈娟娟,骆秀琴,缪殷姝,等.细节护理在重症肌无力患者中的应用效果[J].医学信息,2020,33(10):182.[doi:10.3969/j.issn.1006-1959.2020.10.057]
　QU Juan-juan,LUO Xiu-qin,MOU Yin-shu,et al.Application Effect of DetailedNursing in Patients with Myasthenia Gravis[J].Journal of Medical Information,2020,33(16):182.[doi:10.3969/j.issn.1006-1959.2020.10.057]
[3]高建娣,裘 妃,王秀玲.以球麻痹为唯一表现的儿童重症肌无力1例报道[J].医学信息,2020,33(23):186.[doi:10.3969/j.issn.1006-1959.2020.23.057]

更新日期/Last Update: 2019-08-15